Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741967 | 1.00 | MAPK1 (0.33) | MAPK1NPSR1PGD | |
| SCHEMBL12745739 | 0.83 | MAPK1 (0.31) | MAPK1NPSR1 | |
| SCHEMBL12826667 | 0.83 | MAPK1 (0.31) | MAPK1NPSR1 | |
| SCHEMBL18658564 | 0.83 | MAPK1 (0.31) | MAPK1NPSR1 | |
| SCHEMBL18658547 | 0.82 | MAPK1 (0.34) | MAPK1NPSR1 | |
| SCHEMBL9305518 | 0.82 | MAPK1 (0.34) | MAPK1NPSR1 | |
| SCHEMBL13077136 | 0.81 | — | — | |
| SCHEMBL13077137 | 0.81 | — | — | |
| SCHEMBL18658551 | 0.81 | MAPK1 (0.30) | MAPK1NPSR1 | |
| SCHEMBL18658561 | 0.81 | MAPK1 (0.30) | MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
| EP-1794162-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006091905-A1 | BICYCLO (3.1.0) HEXANE DERIVATIVES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006031505-A1 | PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | MAPK1 1309/4885NPSR1 360/4885PGD 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.